As the treatment landscape for #NMIBC continues to evolve, get the insights you need to know with Medthority. Log in to hear from Joshua Meeks, Félix Guerrero-Ramos, and @ashishkamatmd.bsky.social, plus catch up with highlights from #ESMO25, #ASCO25, and more! #MedSky #OncSky

ow.ly/mFcc50XZKzO

Alliance research at #ESMO25:
✅ PRESTO-Androgen blockade in prostate cancer
✅ PATINA-Improved QoL in breast cancer
✅ ATOMIC-Immune checkpoint inhibitors improve colon cancer survival
✅ CABINET-Improved survival against neuroendocrine tumors
https://bit.ly/ESMO25

What does progress look like for the ALK-positive community?

At #ESMO25, Dr. Ken Culver shared how ALK Positive Inc. advocates for people living with ALK+ lung cancer—bringing science, real-world patient insight, and unmet needs directly to industry and researchers.

PFS Benefit With Lenvatinib/Everolimus Shows Importance of Prioritizing Efficacy Data in ccRCC Treatment Decision-Making | OncLive Andrew W. Hahn, MD, discusses the efficacy and safety of lenvatinib plus everolimus in metastatic ccRCC after progression on PD-1–directed ICIs

PFS Benefit With Lenvatinib/Everolimus Shows Importance of Prioritizing Efficacy Data in ccRCC Treatment Decision-Making @mdanderson.bsky.social #oncology #ESMO25 #rcc
www.onclive.com/view/pfs-ben...

Breast Cancer Breakthroughs: ESMO25 Highlights Share your videos with friends, family, and the world

ICYMI: Breast cancer research breakthroughs discussed at #ESMO25 by @danafarber.bsky.social's Breast Oncology Center. Learn how these discoveries will impact clinical care going forward: 🎥 bit.ly/4j4fa4x

FOG-001 Is Safe, Yields Antitumor Activity in Desmoid Tumors | OncLive FOG-001 demonstrated a manageable safety profile in addition to antitumor activity that was clinically meaningful in patients with desmoid tumors.

FOG-001 Is Safe, Yields Antitumor Activity in Desmoid Tumors
@myesmo.bsky.social #ESMO25
www.onclive.com/view/fog-001...

Although the IMbrave152/SKYSCRAPER-14 trial found that adding tiragolumab to 1L atezo + bev did not improve PFS, other studies are under way to evaluate whether additional checkpoint inhibition might still improve outcomes.
#ESMODailyReporter: https://ow.ly/Bfy950XGUCF

#ESMO25

Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC | OncLive Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.

Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC #ESMO25 #kcsm #oncology www.onclive.com/view/real-wo...

Patients With CML Living in LMICs May Reach High TFR Rates - Oncology Nurse Advisor Researchers evaluated long-term outcomes among patients with CML living in LMICs who received imatinib through financial assistance from the Max Foundation.

Treatment-free relapse is a feasible target for patients with #chronicMyeloidLeukemia living in low- and middle-income countries. Presented at #ESMO25, from @hematologyadvisor.bsky.social.

https://bit.ly/4ppEsMq

#CML #leusm

What’s missing in current clinical guidelines on prostate cancer that every new specialist should know? Alicia Morgans shares her opinion at #ESMO25, including the importance of mitigating the risk of comorbidities #MedSky #OncSky #ProstateCancer #Movember

ow.ly/ap8W50XyGu2

Avelumab Does Not Meaningfully Prolong Survival in Advanced Penile Cancer - Oncology Nurse Advisor Immune checkpoint inhibitors have shown efficacy in other HPV-related cancers, so a phase 2 trial tested the anti-PDL-1 antibody avelumab in patients with locally advanced or metastatic penile cancer with or without previous platinum-based chemotherapy.

A subset of patients with refractory advanced #penilecancer may respond to the immune checkpoint inhibitor avelumab, but how to identify these patients is unclear. From @renalurologynews.bsky.social.

https://bit.ly/43PJkC8

#ESMO25

What are the #NMIBC updates from #ESMO25 you need to know? @ashishkamatmd.bsky.social and Paolo Gontero unpack the latest insights from last month's event, including the impact of BCG therapy shortages and how AI-driven pathology is reshaping risk stratification #MedSky #OncSky

ow.ly/LPaL50Xy4ZJ

Our #BreastCancerBreakthroughs webinar in now online!
Watch Drs. Burstein, Tolaney, Lin, Lynce, and Garrido-Castro, discuss important #BreastCancer research presented at #ESMO25.
👉https://www.youtube.com/watch?v=J6Ma_r31M1M

SCRI's Dr. Erika Hamilton shares updates in HER2+ breast cancer and explains how T-DXd is moving into curative settings, with DESTINY-Breast11 & 05 trials showing:
✅ 83% pCR rate
✅ Anthracycline-sparing
✅ Better disease-free survival
www.medpagetoday.com/meetingcover...
#ESMO25 #BreastCancer

TOP3 Hightlights in #LungCancer from #ESMO25 YouTube video by OncoAlert 360

Our @oncoalert.bsky.social 🚨Faculty Biagio Ricciuti 🇺🇸with his TOP picks of #LungCancer 🫁 WATCH HERE 👉 www.youtube.com/watch?v=eRIS...
#ESMO25

Genentech: Press Releases | Monday, Nov 17, 2025 Discover the latest news about our company, our products, our policies, and our people.

🔴 #Breaking : #Giredestrant 🧬 de #Genentech devient la première #SERD orale à montrer une survie invasive sans maladie supérieure dans le #CancerDuSein précoce.

👉 Résultats positifs de phase III de l’étude #LidERA

#BreastCancer 🦀 #ESMO25
www.gene.com/media/press-...

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma | OncLive AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma @myesmo.bsky.social #ESMO25 #oncology #melsm www.onclive.com/view/amt-253...

A One-Tenth Dose of Pembrolizumab Increases Complete Response in TNBC - Oncology Nurse Advisor “Low-dose pembrolizumab increased complete pathological response when added to dose-dense taxane backbone in patients with stage II to III triple-negative breast cancer,” said Atul Batra, MD.

In triple-negative #breastcancer, pembrolizumab at a tenth of the current standard dose, plus chemotherapy, increased pathologic pCR compared to chemotherapy alone. Presented at #ESMO25, covered by @cancertherapyadv.bsky.social.

https://bit.ly/4hUF1vb

#TNBC #bcsm

🫁 This #LungCancerAwarenessMonth, catch up with the latest trial data from #ESMO25 on non-small-cell lung cancer (NSCLC). From treatment guidance to "reassuring" trial outcomes, get the updates you need to know on Medthority #MedSky #LungCancer

ow.ly/fnwp50XqsyE

EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate

Pretreatment Immune Composition Influences CAR-T Efficacy in DLBCL All patients with detectable circulating B cells prior to treatment achieved complete remission.

Pretreatment blood signatures in patients with #DLBCL may indicate the likelihood of successful CAR T-cell therapy outcomes and could guide pretherapeutic approaches. Presented at #ESMO25.

https://bit.ly/3Ll4MIU

#lymsm #lymphoma

EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer - VJOncology Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II EMPRESS...

At #ESMO25, Dr Llombart Cussac presents #EMPRESS trial results: giredestrant led to greater Ki67 reduction and stronger ER/PR decreases vs tamoxifen in premenopausal ER+/HER2- early #BreastCancer.

🎥 Watch: buff.ly/vLWxnoe

#BCSM #CTSM #TrialUpdate #Oncology

Did you know you can watch exclusive Medthority videos on YouTube? Head over to our channel for expert perspectives on a range of specialties, from congress highlights at #ESMO25 to insights on shared decision-making in atrial fibrillation #MedSky #MedEd

ow.ly/fult50Xn2wX

Metastatic breast cancer updates at ESMO 2025 - VJOncology Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast...

🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.

Watch here ➡️ buff.ly/E4FLjXD

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25

Adding Nimotuzumab to Chemoradiotherapy Does Not Improve Survival in HNSCC - Oncology Nurse Advisor “latinum-based chemoradiotherapy is a hard combo to beat,” said N. Gopalakrishna Iyer, MBBS, PhD, noting that the researchers were “quite surprised” by the overall survival achieved in the control arm, given the real-world setting of the trial.

Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with #HNSCC. Presented at #ESMO25.

https://bit.ly/47oCYMb

#hncsm #headandneckcancer

RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease

🎥 buff.ly/dLhijGf

#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25

What does Félix Guerrero-Ramos think of upcoming shifts in clinical practice when managing #NMIBC? Guerrero-Ramos discusses what he’d like to see in future guidelines, including biomarker selection and better patient classification, at #ESMO25 #MedSky #OncSky

ow.ly/pX2E50XooEi

Dear Colleagues in #ESMO25
Our Collaborators at @mirrorsmed would like to Invite you to Join The Global Forum on GU Oncology info here👉https://gu-global-forum.org

December 3-6, 2025 in Lisbon🇵🇹or ONLINE as this is a HYBRID meeting.

OncoAlert 🚨will be Live from Lisbon covering this Great meeting

Press Release: Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer A new clinical trials shows that pembrolizumab, a drug that utilizes the body’s immune system to target and eliminate cancer cells, appeared to reduce the risk of distant metastases for an aggressive ...

#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa